Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Sai Parenteral'sNSE:SAIPARENT +5.28%14 Net Margin % is 0.55% as of Sep. 2025, which is 88% below its 10-year median of 4.52. GuruFocus rates NSE:SAIPARENT with a GF Score™ of 14/100. The stock has 7 warning signs investors should review. Among 960 Drug Manufacturers companies, Sai Parenteral's ranks worse than 65.21% on this metric.
The historical rank and industry rank for Sai Parenteral's's Net Margin % or its related term are showing as below:
NSE:SAIPARENT'
s Net Margin % Range Over the Past 10 Years
Min: 0.55 Med: 4.52 Max: 5.47
Current: 0.55
NSE:SAIPARENT's Net Margin % is ranked worse than 65.21% of 960
companies
in the Drug Manufacturers industry
Industry Median: 5.33
vs NSE:SAIPARENT: 0.55
Sai Parenteral's (NSE:SAIPARENT) Net Margin % Explanation
Although Net Income and Earnings-per-Share (EPS) are the most widely used parameter in measuring a company's profitability and valuation, it is the least reliable. The reason is that reported earnings can be manipulated easily by adjusting any numbers such as Depreciation, Depletion and Amotorization and non-recurring items.
But the long term trend of the net margin is a good indicator of the competitiveness and health of the business.
Sai Parenteral's Net Margin % Related Terms
Sai Parenteral's Net Margin % Historical Data
* Premium members only.
The historical data trend for Sai Parenteral's's Net Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Sai Parenteral's Net Margin % Chart
Sai Parenteral's Annual Data
Trend
Mar23
Mar24
Mar25
Net Margin %
4.52
5.47
3.97
Sai Parenteral's Semi-Annual Data
Mar23
Mar24
Mar25
Sep25
Net Margin %
0.00
0.00
0.00
0.55
NSE:SAIPARENT vs LLY, JNJ, ABBV: Net Margin % Comparison
For the Drug Manufacturers - General subindustry, Sai Parenteral's's Net Margin %, along with its competitors' market caps and Net Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Sai Parenteral's Net Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Sai Parenteral's's Net Margin % distribution charts can be found below:
* The bar in red indicates where Sai Parenteral's's Net Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Sai Parenteral's (NSE:SAIPARENT) has a Net Margin % of 0.55% as of Sep. 2025. Net margin is the ratio of total net income to net sales. View historical data on Sai Parenteral's and its competitors. This is 88% below median its historical median of 4.52. Over the past decade, Sai Parenteral's' Net Margin % has ranged from 0.55 to 5.47. According to the industry distribution chart, Sai Parenteral's ranks #626 out of 960 companies in the Drug Manufacturers industry, placing it in the top 65.2%.
Is Sai Parenteral's' Net Margin % too high?
Sai Parenteral's' current Net Margin % of 0.55% is 88% below median its 10-year median of 4.52. Over the past 10 years, this metric has ranged from a low of 0.55 to a high of 5.47. The Drug Manufacturers industry median Net Margin % is 5.33. Sai Parenteral's' value of 0.55% is 89.7% below this industry median. Based on the distribution chart, Sai Parenteral's ranks #626 out of 960 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Sai Parenteral's has a GF Score™ of 14/100, reflecting its overall financial health beyond just this single metric.
How does Sai Parenteral's' Net Margin % compare to LLY and JNJ?
According to the Drug Manufacturers industry distribution chart, Sai Parenteral's ranks #626 out of 960 companies for Net Margin %. This places Sai Parenteral's in the lower half of its industry. The industry median Net Margin % is 5.33. Sai Parenteral's' value of 0.55% is 89.7% below this benchmark. Historically, Sai Parenteral's' own Net Margin % has ranged from 0.55 to 5.47 over the past decade. While the company's 10-year median is 4.52 vs. the industry median of 5.33, Sai Parenteral's has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Margin % for a Drug Manufacturers company?
The median Net Margin % among Drug Manufacturers companies is 5.33, based on 960 companies in the industry. Companies in the top quartile (top 25%) have a Net Margin % significantly above this median, while those in the bottom quartile fall well below. However, Net Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Sai Parenteral's's current Net Margin % of 0.55% is 89.7% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Margin % mean?
A high Net Margin % can signal that a stock is expensive relative to its fundamentals. Net margin is the ratio of total net income to net sales. View historical data on Sai Parenteral's and its competitors. For the Drug Manufacturers industry, the median Net Margin % is 5.33 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Sai Parenteral's's current Net Margin % is 0.55%, which is 88% below median its own 10-year median of 4.52. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sai Parenteral's stock overvalued right now?
Sai Parenteral's (NSE:SAIPARENT) has a current Net Margin % of 0.55%. The current Net Margin % is 0.55%, which is 88% below median its 10-year median of 4.52 and 89.7% below the Drug Manufacturers industry median of 5.33. Sai Parenteral's' overall GF Score™ is 14/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Margin % calculated?
Net Margin % is calculated from a company's financial statements. For Sai Parenteral's (NSE:SAIPARENT), the current Net Margin % is 0.55% as of Sep. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Sai Parenteral's Ltd is a diversified pharmaceutical formulations company. Its business is organised in two verticals: (i) Branded Generic Formulations: Through the branded generics portfolio, it serves the domestic market with formulations across multiple therapeutic areas. and (ii) Contract Development and Manufacturing Organisation (CDMO): It provides CDMO services to pharmaceutical companies, supporting activities from product development to commercial manufacturing. Its product portfolio includes cardiovascular care, neuropsychiatry, anti-diabetic therapy, respiratory health, antibiotics, gastroenterology, vitamins, etc. The majority of the company's revenue is derived from the Branded Generic Formulations business.
14GF Score
Get the complete analysis for NSE:SAIPARENT
Net Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:SAIPARENT has been successfully added to your 
